bpc-157 fda status 2025 2026 If worked as well as the internet says it does… …we'd probably have high quality human trials by now. Instead we have... Lots of rat studies. Lots of podcasts. Lots of FDA July 2026 Peptide Meeting:
Description
This reduced space leaves minimal room for the ligament to move, potentially increasing the risk of wear and tear and raising the likelihood of rupture or partial tears in the ACL

Marla R

The FDAs current safety page continues to cite concerns about immunogenicity, peptide impurities and limited safety data, and the agency has stated that a substance may still pose significant safety risks

Theres no definitive study on the duration of results from this application of Botox, yet

doi: 10.1016/j.nbd.2021.105295
